| Identification | More | [Name]
Ivabradine hydrochloride | [CAS]
148849-67-6 | [Synonyms]
Ivabradine HCl
Ivabradine hydrochloride
3-[3-[[(8S)-3,4-Dimethoxy-8-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one hydrochloride
3-[3-[[[(7S)-3,4-Dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one Hydrochloride
Corlentor
Procoralan
S-16257 | [EINECS(EC#)]
638-798-3 | [Molecular Formula]
C27H36N2O5.HCl | [MDL Number]
MFCD00929899 | [Molecular Weight]
505.05 | [MOL File]
148849-67-6.mol |
| Chemical Properties | Back Directory | [Melting point ]
193-196?C | [alpha ]
58921 +7.8°; 36521 +27.8° (c = 1% in DMSO) | [storage temp. ]
2-8°C | [solubility ]
H2O: ≥5mg/mL (warmed) | [form ]
powder | [color ]
white to beige | [optical activity]
[α]/D +5 to +9°, c = 1 in DMSO | [Water Solubility ]
H2O: ≥5mg/mL (warmed) | [Usage]
Selective bradycardic agent with direct effect on the pacemaker If current of the sinoatrial node. Antianginal | [Merck ]
14,5247 | [InChIKey]
HLUKNZUABFFNQS-ZMBIFBSDSA-N | [SMILES]
C([C@H]1CC2=CC(OC)=C(OC)C=C12)N(C)CCCN1CCC2=CC(OC)=C(OC)C=C2CC1=O.Cl |&1:1,r| | [CAS DataBase Reference]
148849-67-6(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Description]
In an effort to develop angina agents without the unwanted negative
inotropic and hypotensive effects associated with b-adrenergic blockers and
calcium channel blockers, a new class of heart-rate reducing compounds that act
specifically on the sinoatrial (SA) node has been explored. These bradycardic
agents interact directly with the pacemaking cell of the SA node and the hyperpolarization-
activated If , the primary pacemaking current. Ivabradine has
evolved as a specific inhibitor of If current through its contact with f-channels on
the intracellular side of the plasma membrane. As a consequence, ivabradine
reduces the speed of diastolic depolarization and decreases heart rate. It has been
approved for the treatment of chronic stable angina and provides a viable
alternative to patients with a contraindication or intolerance of b-blockers. Evaluation
is also underway for the potential treatment of ischemic heart disease.
Using a patch-clamp technique on rabbit sinoatrial node cells, inhibition of If
current ranged from 6% (0.03 mM) – 80% (10 mM).
. | [Chemical Properties]
White to Off-White Solid | [Originator]
Servier (France) | [Uses]
angina therapeutic | [Uses]
Ivabradine HCl, a new If inhibitor with IC 50 of 2.9 μM which acts specifically on the pacemaker activity of the sinoatrial node, is a pure heart rate lowering agent | [Uses]
Selective bradycardic agent with direct effect on the pacemaker If current of the sinoatrial node. Antianginal | [Definition]
ChEBI: A hydrochloride obtained by combining ivabradine with one molar equivalent of hydrochloric acid. Used to treat patients with angina who have intolerance to beta blockers and/or heart failure. | [Brand name]
Procoralan | [Biochem/physiol Actions]
Ivabradine is used to treat chronic heart failure. | [Clinical Use]
Symptomatic treatment of chronic stable angina pectoris
in patients with sinus rhythm
Treatment of mild to severe chronic heart failure | [Drug interactions]
Potentially hazardous interactions with other drugs
Anti-arrhythmics: increased risk of ventricular
arrhythmias with amiodarone and disopyramide.
Antibacterials: concentration possibly increased by
clarithromycin and telithromycin - avoid; increased
risk of ventricular arrhythmias with erythromycin -
avoid.
Antifungals: concentration increased by ketoconazole
- avoid; concentration increased by fluconazole -
reduce initial ivabradine dose; concentration possibly
increased by itraconazole - avoid.
Antimalarials: increased risk of ventricular
arrhythmias with mefloquine.
Antipsychotics: increased risk of ventricular
arrhythmias with pimozide.
Antivirals: concentration possibly increased by
ritonavir - avoid.
Beta-blockers: increased risk of ventricular
arrhythmias with sotalol.
Calcium-channel blockers: concentration increased
by diltiazem and verapamil - avoid.
Grapefruit juice: ivabradine concentration increased.
Pentamidine: increased risk of ventricular
arrhythmias.
St John’s wort: ivabradine concentration reduced -
avoid. | [Metabolism]
Ivabradine is extensively metabolised by the liver
and the gut by oxidation through cytochrome P450
3A4 (CYP3A4) only. The major active metabolite is
N-desmethyl-ivabradine (S 18982) with an exposure
about 40% of that of the parent compound. This active
metabolite undergoes further metabolism by CYP3A4.
Excretion of metabolites occurs to a similar extent via
faeces and urine. | [storage]
Store at -20°C |
|
|